Physician profile
Nicholas Testa
NPI 1225769722
$2,225.56
in general payments reported to CMS, 2019-2025
10 companies · $407 in 2025
The $407 reported for 2025 was more than what 76% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $436 · 2024: $1,260 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328 · Travel and Lodging: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.86 |
| Travel and Lodging | $775.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Cardiovascular Systems Corporation | $867.91 | 2024 | Virtuosaph Plus With Radial Indication |
| Abiomed | $708.09 | 2022-2025 | Impella |
| Haemonetics Corporation | $205.26 | 2023-2025 | Teg6s Hemostasis System, Teg5000 Hemostasis Analyzer |
| Zimmer Biomet Holdings, INC. | $168.85 | 2023 | Sternalock Blu System |
| La Jolla Pharmaceutical Company | $103.41 | 2024-2025 | Giapreza |
| Ethicon US, LLC | $53.11 | 2024 | Stratafix |
| Lemaitre Vascular, INC. | $39.08 | 2023 | Cardiocel, Tyke, Patch, Pledget and Intracardiac |
| Atricure, INC. | $36.32 | 2024 | |
| Getinge USA Sales, LLC | $23.67 | 2023 | Vasoview Hemopro 2 |
| Janssen Pharmaceuticals, INC | $19.86 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Testa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.